- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03238001
Evaluation of DCTclock™ as a Cognitive Assessment Aid
March 5, 2018 updated by: Digital Cognition Technologies
The overall objective of this study is to demonstrate the safety and effectiveness of DCTclock as an adjunctive tool for use by clinicians to evaluate cognitive function in adults aged 55-95.
Study Overview
Study Type
Interventional
Enrollment (Actual)
450
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Florida
-
Maitland, Florida, United States, 32751
- Compass Research
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
51 years to 91 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Men and women 55 to 95 years old.
Exclusion Criteria:
- Ineligible for written informed consent.
- Physical impairment of the writing hand.
- Impaired manual dexterity.
- Impaired vision.
- Under the influence of recreational drugs or alcohol at the time of the visit.
- Current or recent participation in a clinical trial that includes the use of a drug or intervention to alter cognitive function.
- Recent cognitive testing.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Screening
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: All qualified participants
Participants received DCTclock, Mini-Mental State Examination (MMSE), Montreal Cognitive Assessment (MoCA), and a battery of other traditional pen and paper neuropsychological assessments.
|
DCTclock is a quick and non-invasive test that measures cognitive function based on a computerized algorithmic analysis of the entire drawing process and output of a well-established cognitive assessment called The Clock Drawing Test (CDT).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Non-Inferiority of DCTclock Compared to Mini-Mental State Examination (MMSE)
Time Frame: Visit 1 (day 1)
|
The primary analysis will assess agreement between DCTclock and the Montreal Cognitive Assessment (MoCA) and compare it to the agreement between the MMSE and MoCA at visit 1.
|
Visit 1 (day 1)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Quadratic Weighted Kappa on Primary Endpoints
Time Frame: Visit 1 (day 1)
|
Quadratic weighted Cohen's kappa with 95% CI between DCTclock and MoCA, as well as between MMSE and MoCA.
|
Visit 1 (day 1)
|
|
Percent Agreement on Primary Endpoints
Time Frame: Visit 1 (day 1)
|
Positive percent agreement, version A (treating the "Indeterminate" group as "Unimpaired") and version B (removing the "Indeterminate" group from the analysis), and negative percent agreement version A and version B. These were calculated for the DCTclock/MoCA classification table as well as the MMSE/MoCA classification table.
95% CI were also calculated and compared between the two classification tables' calculations.
|
Visit 1 (day 1)
|
|
Regression Coefficients on Primary Endpoints
Time Frame: Visit 1 (day 1)
|
Linear and rank-linear regression coefficients (slope, intercept) and 95% CI for DCTclock regressed on MoCA as well as for the MMSE regressed on MoCA.
|
Visit 1 (day 1)
|
|
Correlation Coefficients on Primary Endpoints
Time Frame: Visit 1 (day 1)
|
Pearson and Spearman correlation coefficients between DCTclock and MoCA as well as between MMSE and MoCA.
|
Visit 1 (day 1)
|
|
Quadratic Weighted Kappa on Secondary Endpoints (Test-Retest Reliability)
Time Frame: Visit 1 and visit 2, occurring 1-4 weeks apart
|
Quadratic weighted Cohen's Kappa statistics were calculated for both DCTclock and MMSE test-retest data (visit 1 vs visit 2).
|
Visit 1 and visit 2, occurring 1-4 weeks apart
|
|
Percent Agreement on Secondary Endpoints (Test-retest Reliability)
Time Frame: Visit 1 and visit 2, occurring 1-4 weeks apart
|
Positive percent agreement version A (treating the "Indeterminate" group as "Unimpaired") and version B (removing the "Indeterminate" group from the analysis), negative percent agreement version A and version B, indeterminate percent agreement, and unimpaired percent agreement.
|
Visit 1 and visit 2, occurring 1-4 weeks apart
|
|
Regression Coefficients on Secondary Endpoints (Test-retest Reliability)
Time Frame: Visit 1 and visit 2, occurring 1-4 weeks apart
|
Deming, linear, and rank-linear correlation coefficients (intercept, slope) were calculated for visit 1 regressed on visit 2 for both DCTclock and MMSE.
|
Visit 1 and visit 2, occurring 1-4 weeks apart
|
|
Correlation Coefficients on Secondary Endpoints (Test-retest Reliability)
Time Frame: Visit 1 and visit 2, occurring 1-4 weeks apart
|
Pearson and Spearman correlation coefficients were calculated between visit 1 and visit 2 for DCTclock and MMSE, along with 95% CI.
|
Visit 1 and visit 2, occurring 1-4 weeks apart
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Construct Validity of DCTclock as Measured by the Comparison of DCTclock Results to the Results of a Battery of Neuropsychological Assessments
Time Frame: Visit 1 (day 1)
|
The goal of this analysis is to assess the construct validity of DCTclock.
Specifically, the goal is to compare scores from the administration of DCTclock to the visit 1 administration of a battery of neuropsychological tests, to characterize the psychometric properties of DCTclock, and to compare those properties to the properties of MMSE.
|
Visit 1 (day 1)
|
|
Incidence of Serious Device-related Adverse Events [Safety]
Time Frame: Visit 1 and visit 2, occuring 1-4 weeks apart
|
Incidence of serious device-related adverse events.
|
Visit 1 and visit 2, occuring 1-4 weeks apart
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Antonia H Holway, Ph.D., Digital Cognition Technologies, Inc.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Lamar M, Ajilore O, Leow A, Charlton R, Cohen J, GadElkarim J, Yang S, Zhang A, Davis R, Penney D, Libon DJ, Kumar A. Cognitive and connectome properties detectable through individual differences in graphomotor organization. Neuropsychologia. 2016 May;85:301-9. doi: 10.1016/j.neuropsychologia.2016.03.034. Epub 2016 Mar 30.
- Souillard-Mandar W, Davis R, Rudin C, Au R, Libon DJ, Swenson R, Price CC, Lamar M, Penney DL. Learning Classification Models of Cognitive Conditions from Subtle Behaviors in the Digital Clock Drawing Test. Mach Learn. 2016 Mar;102(3):393-441. doi: 10.1007/s10994-015-5529-5. Epub 2015 Oct 20.
- Cohen J, Penney DL, Davis R, Libon DJ, Swenson RA, Ajilore O, Kumar A, Lamar M. Digital Clock Drawing: differentiating "thinking" versus "doing" in younger and older adults with depression. J Int Neuropsychol Soc. 2014 Oct;20(9):920-8. doi: 10.1017/S1355617714000757. Epub 2014 Sep 15.
- Davis R, Libon DJ, Au R, Pitman D, Penney DL. THink: Inferring Cognitive Status from Subtle Behaviors. Proc Conf AAAI Artif Intell. 2014 Jul;2014:2898-2905.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 11, 2017
Primary Completion (Actual)
November 21, 2017
Study Completion (Actual)
November 21, 2017
Study Registration Dates
First Submitted
July 27, 2017
First Submitted That Met QC Criteria
July 31, 2017
First Posted (Actual)
August 3, 2017
Study Record Updates
Last Update Posted (Actual)
April 3, 2018
Last Update Submitted That Met QC Criteria
March 5, 2018
Last Verified
March 1, 2018
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- DCT032
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
IPD Plan Description
We do not plan to share IPD
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cognitive Function
-
National Taipei University of Nursing and Health...Active, not recruitingCognitive Function | Physical FunctionTaiwan
-
University School of Physical Education in WroclawActive, not recruitingCognitive Function | Executive FunctionPoland
-
Maastricht UniversityWageningen University and Research; Top Institute Food and Nutrition; Netherlands...TerminatedCognitive Function | Ageing | Physical Function | Mitochondrial FunctionNetherlands
-
University Hospital, GenevaCompletedCognitive Function | Falls | Physical FunctionSwitzerland
-
University of FloridaNational Institutes of Health (NIH); National Institute on Aging (NIA)CompletedCognitive Function | Older Adults | Physical FunctionUnited States
-
Columbia UniversityNational Institute on Aging (NIA)Terminated
-
Örebro University, SwedenActive, not recruitingCognitive FunctionSweden
-
Radicle ScienceCompletedCognitive FunctionUnited States
-
Radicle ScienceCompletedCognitive FunctionUnited States
-
Radicle ScienceCompletedCognitive FunctionUnited States
Clinical Trials on DCTclock
-
Linus Health, Inc.CompletedCognitive FunctionUnited States